Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258315 | 0.90 | BAZ2B (0.46) | BAZ2BNPC1RAB9AITGB3ITGA2B | |
| SCHEMBL7260378 | 0.85 | TP53 (0.47) | BAZ2BNPC1RAB9AITGB3ITGA2B | |
| SCHEMBL11741915 | 0.84 | NPC1 (0.44) | BAZ2BNPC1RAB9AITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL7289438 | 0.82 | SIGMAR1 (0.46) | BAZ2BNPC1RAB9AITGB3ITGA2B | |
| SCHEMBL8432255 | 0.81 | MTNR1A (0.62) | BAZ2BKDM2BMTNR1AKDM4EALDH1A1 | |
| SCHEMBL5582823 | 0.81 | ITGB3 (0.66) | BAZ2BNPC1RAB9AITGB3ITGA2B | |
| SCHEMBL10341502 | 0.80 | ITGB3 (0.59) | BAZ2BNPC1RAB9AITGB3ITGA2B | |
| SCHEMBL5582711 | 0.80 | BAZ2B (0.52) | BAZ2BNPC1RAB9AITGB3ITGA2B | |
| SCHEMBL10341504 | 0.79 | BAZ2B (0.51) | BAZ2BNPC1RAB9AITGB3ITGA2B | |
| SCHEMBL14454770 | 0.79 | ITGB3 (0.53) | BAZ2BNPC1RAB9AITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | BAZ2B 1322/4885NPC1 1085/4885RAB9A 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.